[Clinical and biochemical aspects in the treatment of acute maxillary sinusitis with antioxidants].
A trial has been made of traditional versus antioxidant treatment of acute maxillary sinusitides. The patients were injected a mixture consisting of 4 ml emulsion of 10% dibunol liniment and 2 ml of 5% ascorbic acid made by dilution of 10 g dibunol in 30 ml sterile 0.5% novocaine solution. The mixture was introduced into the sinuses 2 times a day, in one of the study groups it was combined with 500,000 U of ampicillin in cases of purulent sinusitis. In catarrhal form the mixture was injected once a day without the antibiotic. Control groups received 4 ml dioxidine in a single dose after the sinus lavage in catarrhal sinusitis and 500,000 U ampicillin plus hydrocortisone emulsion (1 ml in 4 ml solution) 2 times a day in case of purulent sinusitis. All the patients received aevit (one capsule daily). The mean number of manipulations for the study groups were 4.4 +/- 0.4 in catarrhal sinuses and 6.3 +/- 0.5 in purulent sinusitis; in control groups, respectively, 5.9 +/- 0.5 and 10.7 +/- 0.7. Mean duration of treatment reached 5.3 +/- 0.4, 6.2 +/- 0.3 and 7.1 +/- 0.1 in the study groups and 8.5 +/- 0.2, 10.2 +/- 0.4 days in the control groups. Positive response to the treatment with antioxidants was confirmed by positive changes in blood levels of LPO products, activity of lysosomal hydrolases and antioxidant defense enzymes. The results obtained justify the inclusion of antioxidants in the schemes of acute sinusitis treatment.
Nikolaev
M P
MP
Logunov
A I
AI
Tsyrulńikova
L G
LG
Dzhalilov
D S
DS
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use; D002084:Butylated Hydroxytoluene / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D015227:Lipid Peroxidation; D008297:Male; D015523:Maxillary Sinusitis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D011343:Procaine / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D013492:Suppuration; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000975:Antioxidants; D011810:Quinoxalines; C001077:dioxidine; D002084:Butylated Hydroxytoluene; D011343:Procaine; D000667:Ampicillin; D001205:Ascorbic Acid; D006854:Hydrocortisone
Kliniko-biokhimicheskie obosnovaniia primeneniia antioksidantov v lechenii ostrykh verkhnecheliustnykh sinusitov.